Different substances, populations and levels of clinical evidence.
Bottom line: The CJC-1295 studies cited here measured hormone levels. They did not test the no-DAC/ipamorelin mix for recovery, sleep or general body composition. Tesamorelin is approved for adults with HIV-associated lipodystrophy. [1–4]
| CJC-1295 / Ipamorelin | Tesamorelin | |
|---|---|---|
| What the evidence concerns | Long-acting CJC-1295 in short hormone studies, not the marketed no-DAC/ipamorelin combination. [1] | Tesamorelin in adults with HIV-associated lipodystrophy. [2–4] |
| Established use | No established sleep, recovery or body-composition indication for the combination. [1,5] | Reduction of excess abdominal fat in the labeled HIV population. Not general weight management. [2,3] |
| Dose | No validated therapeutic combination dose in these sources. | Egrifta WR: 1.28 mg daily. Egrifta SV: 1.4 mg daily. Product instructions differ. [2,3] |
| Preparation | No approved combined-product preparation instructions. | WR uses its supplied bacteriostatic water; SV uses its supplied sterile water and is administered immediately. [2,3] |
| Safety | FDA identifies safety concerns and limited clinical information for CJC-1295 and ipamorelin. [5] | Glucose intolerance, elevated IGF-1, fluid retention and other labeled risks require monitoring. [2,3] |
tierA: {"tier":1,"label":"Combination benefits not established"}
tierB: {"tier":3,"label":"Approved for a defined HIV population"}
summary: CJC-1295 trials used the long-acting molecule and assessed hormone responses. Tesamorelin's phase 3 evidence concerns excess abdominal fat in adults with HIV-associated lipodystrophy. No direct comparison of these treatments is presented by these sources. [1–4]
trials: []
The cited studies do not demonstrate therapeutic equivalence. An approved treatment for a diagnosed condition should be assessed against that condition's evidence. [1–4]
No. Egrifta WR and SV have different doses and preparation instructions and are not substitutable. Check the exact prescribed product. [2,3]
Educational evidence summary. Approved products, patient-specific compounded preparations, clinical-trial products, and research-market products are not interchangeable categories.
